Every story in this section, newest first — page 185 of 373.
Immuneering (NASDAQ:IMRX), a clinical-stage oncology company developing innovative medicines targeting the MAPK pathway, reported its first-quarter 2026 financial results and provided a corporate update.
BioXcel Therapeutics (NASDAQ:BTAI) announced that the U.S. Food and Drug Administration has formally accepted a supplemental New Drug Application for its lead neuropsychiatric drug, providing a clear regulatory catalyst as the company manages tightening capital constraints.
Traws Pharma (NASDAQ:TRAW) reported a net loss for the first quarter of 2026 as the company aggressively scaled up investments in its respiratory antiviral pipeline, pivoting away from the profitable metrics recorded in the prior year's opening period.
Protara Therapeutics (NASDAQ:TARA) reported updated 12-month interim data from the Cohort A arm of its Phase 2 ADVANCED-2 clinical trial, demonstrating sustained tumor clearance and a favorable safety profile for its lead oncology candidate.
PowerBank (NASDAQ:SUUN) reported a significant expansion in its underlying profit margins and a strengthened balance sheet for the first nine months of fiscal year 2026, driven by systematic execution of its North American clean energy project pipeline.
Indaptus Therapeutics (NASDAQ:INDP) announced a sweeping re-evaluation of its core developmental pipeline and resource allocation alongside a significant leadership transition, signaling a strategic pivot as the company faces tightening liquidity constraints.
Purple Biotech (NASDAQ:PPBT) reported its financial and operational results for the first quarter of 2026, highlighting clinical milestones within its immunotherapy pipeline and a stabilized bottom line supported by non-operating income.
The Board of Directors of Genco Shipping & Trading (NYSE:GNK) has unanimously rejected an unsolicited tender offer from Diana Shipping to acquire all outstanding shares of the company for $23.50 per share in cash, setting up a high-stakes corporate standoff in the global maritime sector.
Tenaya Therapeutics (NASDAQ:TNYA), a clinical-stage biotechnology company developing gene therapies for heart disease, reported positive interim data from the first two cohorts of its ongoing RIDGE-1 Phase 1b/2 trial of TN-401 in patients with PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).
H World Group (NASDAQ:HTHT) reported double-digit revenue and turnover growth for the first quarter of 2026, capitalizating on persistent leisure and business travel demand across its sprawling multi-brand hospitality network.
Seritage Growth Properties (NYSE:SRG) reported a widening net loss for the first quarter of 2026, driven by significant asset impairment charges, while management continues to negotiate the restructuring of its remaining corporate debt ahead of a summer deadline.
ARS Pharmaceuticals (NASDAQ:SPRY) reported its first-quarter 2026 financial results, highlighted by accelerating domestic sales for its needle-free allergy treatment alongside a broadening international regulatory footprint.
A2Z Cust2Mate Solutions (NASDAQ:AZ) reported a more than doubling of its first-quarter revenue for 2026, driven by an accelerating operational pivot from pilot validations to large-scale commercial deployments of its automated shopping platforms.
American Strategic Investment (NYSE:NYC) reported a decline in first-quarter 2026 revenue, reflecting the structural contraction of its New York City commercial real estate portfolio following a major property exit.
Wall Street welcomed its biggest AI hardware listing in years on Thursday, as Cerebras Systems debuted on the Nasdaq with a $66 billion valuation and a 68% first-day rally - capping a bookbuild that was twenty times oversubscribed.
Li Auto (NASDAQ:LI) officially launched the all-new generation of its flagship luxury crossover SUV, the Li L9, positioning the model as a core technological anchor to capture premium market share in the increasingly competitive electric vehicle space.
SanDisk (NASDAQ:SNDK) advised its shareholders to reject an unsolicited "mini-tender" offer from Tutanota, warning that the proposed transaction is structurally engineered to deliver a below-market payout.
Vroom (NASDAQ:VRM reported a widening net loss for the first quarter of 2026, alongside an updated full-year corporate outlook and a planned debt restructuring strategy scheduled to close this summer.
Super League Enterprise (NASDAQ:SLE) reported growing top-line revenue and expanding gross profit margins for the first quarter of 2026, indicating that its recent corporate restructuring is beginning to translate into stronger financial efficiency.
Sensei Biotherapeutics (NASDAQ:SNSE) reported a significantly wider net loss for the first quarter of 2026, primarily driven by massive, one-time accounting charges stemming from its transformational acquisition of Faeth Therapeutics Inc. earlier in the year.
Mako Mining (NASDAQ:MAKO) reported record financial and operational performance for the first quarter of 2026, driven by an unprecedented surge in global bullion prices and production contributions across its expanding North American asset portfolio.
Comstock Holding Companies (NASDAQ:CHCI) reported a 38% surge in first-quarter revenue, bolstered by high occupancy rates across its stabilized portfolio and a record-setting luxury residential sale in Northern Virginia.
Rumble (NASDAQ:RUM) reported a 7% increase in first-quarter revenue and steady user growth as the video platform prepares to finalize its high-stakes acquisition of Northern Data to bolster its cloud and artificial intelligence infrastructure.
Figma (NYSE:FIG) reported a significant acceleration in revenue growth for the first quarter of 2026, outperforming its internal projections as demand for its collaborative design platform reached new highs.
